MERCALIS

Serial Number 97916626
Registration 7892673
700

Registration Progress

Application Filed
May 2, 2023
Under Examination
Oct 8, 2024
Approved for Publication
Aug 13, 2024
Published for Opposition
Aug 13, 2024
Registered
Aug 12, 2025

Trademark Image

MERCALIS

Basic Information

Serial Number
97916626
Registration Number
7892673
Filing Date
May 2, 2023
Registration Date
August 12, 2025
Published for Opposition
August 13, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 12, 2025
Registration
Registered
Classes
035 036 041 042
+1 more

Rights Holder

MERCALIS INC.

03
Address
2250 PERIMETER PARK DRIVE
SUITE 300
MORRISVILLE, NC 275608893

Ownership History

TrialCard Incorporated

Original Applicant
03
Morrisville, NC

MERCALIS INC.

New Owner Before Publication #1
03
MORRISVILLE, NC

MERCALIS INC.

Owner at Publication
03
MORRISVILLE, NC

MERCALIS INC.

Original Registrant
03
MORRISVILLE, NC

Legal Representation

Attorney
Larry L. Coats

USPTO Deadlines

Next Deadline
2058 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250812)
Due Date
August 12, 2031
Grace Period Ends
February 12, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

38 events
Date Code Type Description Documents
Aug 12, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Aug 12, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jul 23, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Jul 23, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jul 18, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Apr 3, 2025 IUAF S USE AMENDMENT FILED Loading...
Jul 16, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 3, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Oct 8, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 13, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 13, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 24, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 11, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 10, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 10, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 10, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 5, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 3, 2024 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Jun 9, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
May 15, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
May 14, 2024 PBCR Z WITHDRAWN FROM PUB - OG REVIEW QUERY Loading...
May 1, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 1, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
May 1, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
May 1, 2024 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
May 1, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Apr 25, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 25, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 25, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 29, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 29, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jan 29, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jan 29, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 15, 2023 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
May 31, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 5, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 035
Business management and administration of pharmacy reimbursement programs; Managing and administering the distribution of prescription pharmaceutical samples to physicians and patients for pharmaceutical manufacturers; Business management and administration of patient co-pay reimbursement programs on behalf of pharmaceutical manufacturers; Business management and administration of financial assistance programs that provide patients with access to affordable medicine, namely business management and administration of enrollment and reimbursement programs for the purchase of medication and generally facilitating access to medications; Business management and administration of patient support programs for pharmaceutical manufacturers; Business management and administration of patient engagement programs for pharmaceutical manufacturers; Business management and administration of formulary, patient, and payer policy information for pharmaceutical, medical device, and diagnostic manufacturers; Business management and administration of educational engagements for Health Care Providers, namely, business management and administration of efforts to educate healthcare providers on medications, disease status and standard of care; Management of the distribution of clinical trial medication and supplies on behalf of pharmaceutical manufacturers; Providing business marketing information, namely, tracking pharmaceutical promotional programs for pharmaceutical manufacturers and evaluating and determining their effectiveness; Data management services in the field of pharmaceutical patient safety, namely, collecting adverse product events data, storing the data, and reporting collected adverse product events data; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, promoting awareness of diseases, pharmaceutical brands, and treatment affordable options; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, marketing services in the nature of promotion of pharmaceutical manufacturers and disease treatment options via social media; Business information services, namely, tracking payer coverage policies and related documentation and providing life sciences clients access to such in order to enhance their market access strategies and patient support programs; Life science business strategy consulting services for assisting clients with commercial assessments, corporate and portfolio strategy, new product planning and commercialization support, and pricing and market access insights; Business assistance services, namely, enrolling patients of pharmaceutical manufacturers into support programs that enable patients to view, track, and manage the support program wherein the patient support program provides pharmaceutical consumer product information, payer coverage status updates, and providing business information regarding access to enrollment and reimbursement programs for the purchase of medications; Providing business information and news to the pharmaceutical and life sciences industries on legislative and regulatory developments as it impacts and relates to the pharmaceutical and life sciences industries within the copay or patient affordability space
First Use Anywhere: Sep 20, 2023
First Use in Commerce: Sep 20, 2023
Class 036
Payment services, namely, reimbursement payment processing in the field of pharmaceutical financial assistance programs and loyalty program payment processing services provided on behalf of pharmaceutical manufacturers for the purpose of delivering benefits to patients enrolled in pharmaceutical manufacturer-sponsored financial assistance programs; Pharmacy benefit manager (PBM) accumulator mitigation services and detecting claim activity indicative of a pharmacy benefit manager attempting to abuse the use of co-pay cards by not applying amounts paid by clients towards the patient's deductible or annual out-of-pocket expense; Anti-kickback and risk mitigation services for the pharmaceutical industry, namely, antikickback compliance services for assuring that patients who have full or partial federally funded drug coverage are excluded from utilizing co-pay cards
First Use Anywhere: Sep 20, 2023
First Use in Commerce: Sep 20, 2023
Class 041
Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, providing podcasts, seminars, workshops, and virtual and in-person presentations for educational purposes in the field of diseases, pharmaceutical brands, and affordable healthcare options
First Use Anywhere: Sep 20, 2023
First Use in Commerce: Sep 20, 2023
Class 042
Quality assurance and quality control patient claim services for monitoring paid claims to patients from insurance or pharmaceutical entities to insure that specific business rules are being correctly applied to patient claims; Pharmacovigilance services for others, namely, scientific research and analysis pertaining to adverse events and product quality complaints regarding pharmaceutical products, assessment of risks presented by certain pharmaceutical products or combinations thereof, and product safety testing and consultation related thereto in the field of pharmaceuticals; Pharmacovigilance services for others, namely, monitoring the quality of efficacy of pharmaceutical preparations; Providing online non-downloadable software for patient support services, namely, for enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services including injection and product educational training, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications
First Use Anywhere: Sep 20, 2023
First Use in Commerce: Sep 20, 2023
Class 045
Pharmacy benefit fraud monitoring, namely, investigation services related to pharmacy benefit insurance claims
First Use Anywhere: Sep 20, 2023
First Use in Commerce: Sep 20, 2023

Classification

International Classes
035 036 041 042 045